IDEXX (IDXX) Bets an AI Scribe Can Sell More Pet Diagnostics

In a strategic move, IDEXX Laboratories (NASDAQ:IDXX) acquired CoVetAI, a rapidly growing veterinary software company, on September 16. While the acquisition price remains undisclosed, IDEXX aims to leverage CoVetAI's capabilities to boost pet diagnostics sales. With over 10,000 clinics already utilizing its cloud practice software, CoVetAI can seamlessly integrate into IDEXX's ecosystem and IDEXX VetConnect PLUS.

This integration provides CoVetAI with a substantial customer base and a ready audience for its innovative product.

Moreover, CoVetAI operates with various practice systems, including those IDEXX does not produce. By supporting rival scribes, IDEXX ensures the tool can reach clinics and regions outside its current reach. The acquisition aligns with IDEXX's recent financial performance, as reported in its second-quarter earnings. The company achieved a 10% revenue growth and an 11% increase in recurring diagnostics business, driven by higher test volumes.

This trend supports IDEXX's belief that a smarter workflow tool, such as CoVetAI, can encourage veterinarians to conduct more tests.

Furthermore, IDEXX has recently expanded its AI-driven product portfolio, with over 1,600 inVue Dx analyzers installed in the quarter, surpassing the 9,000-unit mark. The company's focus on software and hardware integration highlights its commitment to creating a unified AI-driven ecosystem. However, the acquisition's true value remains uncertain due to the lack of deal terms, earnings impact assessment, and potential ROI measurement.

The company's description of the payoff as future-oriented suggests a hopeful outlook, rather than a confirmed outcome.

Nevertheless, IDEXX's strategic decision to acquire CoVetAI could prove advantageous if clinics using the software report increased test orders. This outcome would solidify the deal's value within the already thriving business. Conversely, if the benefits remain theoretical, CoVetAI could become an additional financial burden for IDEXX. Nonetheless, the acquisition demonstrates IDEXX's confidence in the AI-driven future of veterinary diagnostics and its willingness to invest in this burgeoning sector.